MA07.027h, Autonomic Nervous System Testing
Independence Blue Cross reissued MA07.027h on 03/04/2026 to reaffirm the Company's position on autonomic nervous system (ANS) testing. The policy clarifies that ANS testing using noninvasive, portable, automated devices remains experimental/investigational, while formal laboratory-based diagnostic testing is covered only for specific clinical indications. The BILLING REQUIREMENT header has been removed from the policy structure. Billing teams must ensure claims for ANS testing (CPT 95921, 95922, 95923) meet documented medical necessity criteria and are not submitted for screening purposes.